Alto Neuroscience, INC

Alto Neuroscience, Inc. has successfully completed a registered direct offering of common stock, raising approximately $93.9 million to advance its clinical development programs.

Alto Neuroscience announced preliminary cash reserves of approximately $244.2 million as of June 30, 2026, and plans to accelerate clinical development of its ALTO-207 program.

Alto Neuroscience, Inc. has appointed biotechnology veteran Dr. Andrew Miller to its Board of Directors, effective May 27, 2026.

Alto Neuroscience, Inc. has filed an amendment to its 2024 Employee Stock Purchase Plan, approved by stockholders on May 12, 2026, to include pre-funded warrants in share reserve calculations.

Alto Neuroscience reported Q1 2026 results, highlighting the initiation of a Phase 2b trial for ALTO-207 in treatment-resistant depression and a $120 million PIPE financing.

Alto Neuroscience reported that its ALTO-101 drug candidate did not achieve statistical significance on its primary endpoint in a Phase 2 study for cognitive impairment associated with schizophrenia, shifting focus to ALTO-207.

Alto Neuroscience reports a significant increase in R&D expenses for Q1 2026, driven by advancements in its ALTO-101 and ALTO-207 programs, alongside substantial capital raised through private placements.

Alto Neuroscience reports Q3 2025 results, highlighting pipeline advancements for ALTO-101 and ALTO-207, and a $49.9 million private placement extending its cash runway into 2028.

Alto Neuroscience reported increased net losses and cash burn in Q2 2025, but extended its cash runway into 2028 through new financing and operational efficiencies, while advancing multiple clinical programs and acquiring new assets.

Alto Neuroscience reports a net loss of $15.2 million for Q1 2025 and provides updates on its clinical-stage assets targeting psychiatric disorders.

Alto Neuroscience's third quarter report reveals a net loss of $16.8 million and the failure of its Phase 2b trial of ALTO-100 in MDD to meet its primary endpoint, while highlighting ongoing clinical trials and a new convertible loan agreement.

Alto Neuroscience, a clinical-stage biopharmaceutical company, released its second quarter 2024 financial results, highlighting progress in its clinical programs and financial position.

Alto Neuroscience's 2025 annual report highlights progress in its precision psychiatry pipeline with new funding, despite a setback in its ALTO-100 MDD trial.

Alto Neuroscience's 2024 10-K filing details the company's financial status, clinical trial updates, and strategic direction in precision psychiatry.

Alto Neuroscience's 10-K filing outlines the company's stock authorization, preferred stock details, warrant agreements, and compliance with securities regulations.

Director Andrew Craig Miller was granted 26,000 stock options as part of the company's non-employee director compensation policy.

Alto Neuroscience's President and CEO, Amit Etkin, gifted 400,000 shares of common stock to an irrevocable trust for estate planning purposes.

Ramiro Sanchez, a Director at Alto Neuroscience, Inc., acquired 10,958 stock options with an exercise price of $24.63.

Alto Neuroscience Director Christopher Nixon Cox acquired stock options, as disclosed in a Form 4 filing.

Alto Neuroscience, Inc. director Manji Husseini acquired 10,958 stock options with an exercise price of $24.63.

Alto Neuroscience, Inc. director Andrew Dreyfus acquired stock options, as disclosed in a Form 4 filing.

Alto Neuroscience, Inc. announces its 2026 Annual Meeting of Stockholders to address director elections, auditor ratification, and amendments to its equity incentive and employee stock purchase plans.

Alto Neuroscience files an amendment to its proxy statement to include Inline eXtensible Business Reporting Language data tagging that was initially omitted.

Alto Neuroscience, Inc. announces its 2025 Annual Meeting of Stockholders to be held on May 13, 2025, and provides details on accessing proxy materials and voting.

Alto Neuroscience announces its 2025 annual meeting of stockholders to be held virtually on May 13, 2025, to vote on the election of a director and ratification of the company's independent auditor.

Alto Neuroscience is registering an additional 1,541,000 shares of common stock for its public offering, including an underwriter's option.

Alto Neuroscience files an amendment to its S-1 registration statement, primarily to update the filing fee table for its proposed IPO.

Alto Neuroscience is seeking to go public, planning to use proceeds to advance its clinical-stage pipeline and precision psychiatry platform.

Alto Neuroscience, a clinical-stage biopharmaceutical company, has filed for an IPO to advance its precision psychiatry platform and pipeline of personalized treatments for mental health conditions.

EcoR1 Capital, LLC and related entities have reported beneficial ownership of 5.8% of Alto Neuroscience, Inc. common stock following the company's recent offering.

Vestal Point Capital, LP and Ryan Wilder have reported a 6.5% passive ownership stake in Alto Neuroscience, Inc., totaling over 2 million shares.

Commodore Capital LP and its principals have reported a 9.9% beneficial ownership stake in Alto Neuroscience, Inc. via a Schedule 13G filing.

Sirenia Capital Management LP and Alex Silverstein have jointly reported beneficial ownership of 7.9% of Alto Neuroscience, Inc. common stock, including shares issuable upon warrant exercise.

Commodore Capital LP and its affiliates have reported a 9.8% beneficial ownership stake in Alto Neuroscience, Inc., totaling 3,190,267 shares.

Perceptive Advisors and Joseph Edelman have reported a 7.3% beneficial ownership stake in Alto Neuroscience, Inc., totaling 1,989,393 shares.